Showing results (1941-1950 of 2,177) with videos related to

Sort By:
Pageof 218
Nature Communications|June 26, 2024
Tracking single hiPSC-derived cardiomyocyte contractile function using CONTRAX an efficient pipeline for traction force measurementGaspard Pardon, Alison S Vander Roest, Orlando Chirikian, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapyChristina K Augustine, Hiroaki Toshimitsu, Sin-Ho Jung, et al.
European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes|September 11, 2004
Aortic aneurysm repair is associated with a lower inflammatory response compared with surgery for inflammatory bowel diseaseH S A Oldenburg, M P C Siroen, P G Boelens, et al.
Circulation|October 18, 2023
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer CarvedilolKinya Seo, Yuta Yamamoto, Anna Kirillova, et al.
Nature Methods|May 24, 2016
Comparison of Cas9 activators in multiple speciesAlejandro Chavez, Marcelle Tuttle, Benjamin W Pruitt, et al.
The Journal of Clinical Investigation|August 13, 2013
Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeJens Dannull, N Rebecca Haley, Gary Archer, et al.
Contemporary Clinical Trials Communications|April 16, 2024
Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel programChika Nwachukwu, Sukh Makhnoon, Marieshia Person, et al.
Molecular Cancer|September 2, 2014
microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancerJack W Rostas, Hawley C Pruitt, Brandon J Metge, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell CarcinomaEric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
Pageof 218